1. **NEW NORDISK $NVO-0.9% ATTRACTIVE GROWTH INVESTMENT**

- Novo Nordisk is a Danish pharmaceutical company with excellent financial growth. -

It is currently attracting the attention of growth investors in the market.

2. **Key factors for investors:**

- Earnings growth: Historically, the company has earnings per share (EPS) growth of 13.5%, with expected growth for this year of up to 18.4%.

- Asset utilization ratio: Novo Nordisk's sales to total assets (S/TA) ratio is 0.79, indicating efficient business operations.

3. **Zacks Rank and Growth Style Score:**

- The company has received significant rankings Zacks Rank (Strong Buy) and in the Zacks Growth Style Score, indicating excellent growth prospects.

4. **Revenue growth and favorable estimate adjustments:**

- Novo Nordisk expects sales growth of 18.7% this year, above the industry average of 3.9%.

- The trend of upward revisions to earnings estimates supports the positive outlook.

5. **Attractive investment opportunity for growth investors:**

- Overall ,$NVO-0.9% is considered an attractive growth investment with future prospects and attracts investors looking for growth potential.

How do you investors like the company?